- Details
- Description
-
Packaging Size30t/bottle
-
Strength200mg
-
CompositonPretomanid
-
TreatmentMultidrug-resistant tuberculosis (MDR-TB)
-
FormTablet
-
BrandLuciPret
-
Quantity Unit200mg*30t/box
-
ManufacturerLucius Pharmaceuticals (Lao) Co.,Ltd
About Pretomanid
Pretomanid is used as a part of combination dosing regimen with bedaquiline and linezolid to treat tuberculosis (TB) of the lungs that is extensively drug resistant (XDR) or who cannot tolerate or do not respond to treatment for multidrug-resistant (MDR)-TB.
Tuberculosis
Indicated as part of a combination regimen with bedaquiline and linezolid for treatment of adults with pulmonary extensively drug-resistant (XDR) or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB)
Dosage regimen
- Pretomanid 200 mg PO daily x 26 weeks plus bedaquiline and linezolid
-
Bedaquiline dosage regimen options
- 400 mg PO daily x 2 weeks, THEN, 200 mg 3x/week with at least 48 hr between doses for x 24 weeks (total of 26 weeks)
- 200 mg PO daily x 8 weeks, THEN 100 mg PO daily x 18 weeks (total of 26 weeks)
-
Linezolid dosage regimen options
- Preferred regimen: 600 mg PO daily x 26 weeks; if myelosuppression, peripheral neuropathy, or optic neuropathy occurs, reduce dose to 300 mg daily or interrupt linezolid dosing
- Alternant regimen: 1200 mg PO daily for 26 weeks; adjust dose as necessary (600 mg/day, further reduction to 300 mg/day, or interrupt dosing) for myelosuppression, peripheral neuropathy, or optic neuropathy
Dosage Modifications
Renal or hepatic impairment: Effect on the safety, effectiveness, and pharmacokinetics unknown
Hepatotoxicity
-
Interrupt treatment of entire regimen
- Aminotransferase elevations and total bilirubin elevations >2x ULN
- Aminotransferase elevations >8 x ULN
- Aminotransferase elevations >5x ULN and persist beyond 2 weeks
